Compare KD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | PCVX |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 6.1B |
| IPO Year | 2021 | 2020 |
| Metric | KD | PCVX |
|---|---|---|
| Price | $12.56 | $56.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $35.25 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 5.2M | 1.0M |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $15,057,000,000.00 | N/A |
| Revenue This Year | $3.96 | N/A |
| Revenue Next Year | $0.41 | N/A |
| P/E Ratio | $16.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.10 | $28.09 |
| 52 Week High | $43.74 | $76.61 |
| Indicator | KD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 48.83 |
| Support Level | $11.34 | $42.30 |
| Resistance Level | $13.81 | $57.50 |
| Average True Range (ATR) | 0.53 | 2.96 |
| MACD | 0.49 | -0.68 |
| Stochastic Oscillator | 53.83 | 14.14 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.